A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/4745 (2006.01) A61P 35/00 (2006.01) C07D 491/22 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2754646
The present invention provides a humanized anti-EGFR IgG1 antibody and irinotecan for combined use in treating cancer, with or without additional agents or treatments, such as other anti- cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of a combination of a humanized anti-EGFR IgG1 antibody and irinotecan in a pharmaceutically acceptable carrier.
La présente invention porte sur un anticorps anti-IgG1 EGFR humanisé et sur l'irinotécane pour une utilisation combinée dans le traitement du cancer, avec ou sans agent supplémentaire ou traitement supplémentaire, tels que d'autres médicaments anticancéreux ou une radiothérapie. L'invention concerne également une composition pharmaceutique qui est composée d'une combinaison d'un anticorps anti-IgG1 EGFR humanisé et de l'irinotécane dans un support pharmaceutiquement acceptable.
Friess Thomas
Moessner Ekkehard
Moser Samuel
Umana Pablo
Gowling Lafleur Henderson Llp
Roche Glycart Ag
LandOfFree
Treatment of cancer with a humanized anti-egfr igg1 antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancer with a humanized anti-egfr igg1 antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer with a humanized anti-egfr igg1 antibody... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1447953